Multicenter Evaluation of the Bovine Mesenteric Vein Bioprostheses for Hemodialysis Access in Patients with an Earlier Failed Prosthetic Graft

MVB provided superior secondary graft patency compared with both historic graft data or newly implanted nonrandomized synthetic implants. A considerable reduction in thrombosis, infection, and interventions was observed with the MVB graft. These results suggest that MVB offers a safe alternative to patients who have a history of failing synthetic access grafts and may represent an option for extending vascular access to this patient population.